NCT06946901View on ClinicalTrials.gov

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

April 3, 2026

Study Completion Date

December 31, 2027

Conditions
Hyperthermic Intraperitoneal ChemotherapyPeritoneal Metastatic Pancreatic Cancer
Interventions
COMBINATION_PRODUCT

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy

"* HIPEC (cisplatin 70mg/m², Day 1,3 post-surgery), 1 cycle；~* Systemic AG chemotherapy (nab-paclitaxel 125mg/m²+ gemcitabine 1000mg/m², initiated, Day 1,8,15, q4 week), 4 cycles"

Trial Locations (2)

200000

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

410000

NOT_YET_RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER